ATE232098T1 - Verwendung von efaroxan zur herstellung eines arzneimittels zur behandlung von huntington krankheit - Google Patents
Verwendung von efaroxan zur herstellung eines arzneimittels zur behandlung von huntington krankheitInfo
- Publication number
- ATE232098T1 ATE232098T1 AT97938939T AT97938939T ATE232098T1 AT E232098 T1 ATE232098 T1 AT E232098T1 AT 97938939 T AT97938939 T AT 97938939T AT 97938939 T AT97938939 T AT 97938939T AT E232098 T1 ATE232098 T1 AT E232098T1
- Authority
- AT
- Austria
- Prior art keywords
- efaroxan
- disease
- pct
- huntington
- treatment
- Prior art date
Links
- RATZLMXRALDSJW-UHFFFAOYSA-N 2-(2-ethyl-3H-benzofuran-2-yl)-4,5-dihydro-1H-imidazole Chemical compound C1C2=CC=CC=C2OC1(CC)C1=NCCN1 RATZLMXRALDSJW-UHFFFAOYSA-N 0.000 title abstract 2
- 208000023105 Huntington disease Diseases 0.000 title abstract 2
- 229950001765 efaroxan Drugs 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Confectionery (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9610118A FR2752163B1 (fr) | 1996-08-12 | 1996-08-12 | Utilisation de l'efaroxan pour la fabricaton de medicament destine au traitement de la maladie de huntington |
| PCT/FR1997/001480 WO1998006393A1 (fr) | 1996-08-12 | 1997-08-12 | Utilisation de l'efaroxan pour la fabrication de medicament destine au traitement de la maladie de huntington |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE232098T1 true ATE232098T1 (de) | 2003-02-15 |
Family
ID=9494997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97938939T ATE232098T1 (de) | 1996-08-12 | 1997-08-12 | Verwendung von efaroxan zur herstellung eines arzneimittels zur behandlung von huntington krankheit |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6153638A (de) |
| EP (1) | EP0938311B1 (de) |
| JP (1) | JP2001501171A (de) |
| CN (1) | CN1105560C (de) |
| AT (1) | ATE232098T1 (de) |
| AU (1) | AU714437B2 (de) |
| BR (1) | BR9711059A (de) |
| CA (1) | CA2263366A1 (de) |
| DE (1) | DE69718928D1 (de) |
| FR (1) | FR2752163B1 (de) |
| WO (1) | WO1998006393A1 (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8188126B2 (en) * | 2002-05-16 | 2012-05-29 | Pierre Fabre Medicament | Imidazolic compounds and use thereof as alpha-2 adrenergic receptors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK146787A (da) * | 1987-03-23 | 1988-09-24 | Ferrosan | Heterocykliske forbindelser, deres fremstilling og anvendelse |
| EP0451790A1 (de) * | 1990-04-12 | 1991-10-16 | Hoechst Aktiengesellschaft | 3,5-disubstituierte 2-Isoxazoline und Isoxazole, Verfahren zu deren Herstellung, diese enthaltende Mittel und ihre Verwendung |
| US5739284A (en) * | 1992-10-19 | 1998-04-14 | Brigham And Women's Hospital, Inc. | Compositions corresponding to a high-affinity glutamate transporter molecule and methods for making and using same |
| TW264473B (de) * | 1993-01-06 | 1995-12-01 | Hoffmann La Roche | |
| FR2707166B1 (fr) * | 1993-07-09 | 1995-09-29 | Pf Medicament | Utilisation de l'efaroxan et de ses dérivés pour la fabrication de médicaments destinés au traitement de maladies neurodégénératives et leur progression . |
| US5741778A (en) * | 1996-03-19 | 1998-04-21 | Amgen Inc. | Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product |
-
1996
- 1996-08-12 FR FR9610118A patent/FR2752163B1/fr not_active Expired - Fee Related
-
1997
- 1997-08-12 BR BR9711059A patent/BR9711059A/pt not_active Application Discontinuation
- 1997-08-12 CA CA002263366A patent/CA2263366A1/fr not_active Abandoned
- 1997-08-12 CN CN97197794A patent/CN1105560C/zh not_active Expired - Fee Related
- 1997-08-12 AU AU41206/97A patent/AU714437B2/en not_active Ceased
- 1997-08-12 DE DE69718928T patent/DE69718928D1/de not_active Expired - Lifetime
- 1997-08-12 WO PCT/FR1997/001480 patent/WO1998006393A1/fr not_active Ceased
- 1997-08-12 AT AT97938939T patent/ATE232098T1/de not_active IP Right Cessation
- 1997-08-12 EP EP97938939A patent/EP0938311B1/de not_active Expired - Lifetime
- 1997-08-12 US US09/242,314 patent/US6153638A/en not_active Expired - Fee Related
- 1997-08-12 JP JP10509457A patent/JP2001501171A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DE69718928D1 (de) | 2003-03-13 |
| EP0938311A2 (de) | 1999-09-01 |
| CA2263366A1 (fr) | 1998-02-19 |
| JP2001501171A (ja) | 2001-01-30 |
| US6153638A (en) | 2000-11-28 |
| FR2752163B1 (fr) | 1998-10-30 |
| FR2752163A1 (fr) | 1998-02-13 |
| EP0938311B1 (de) | 2003-02-05 |
| AU714437B2 (en) | 2000-01-06 |
| BR9711059A (pt) | 1999-08-17 |
| CN1230113A (zh) | 1999-09-29 |
| WO1998006393A1 (fr) | 1998-02-19 |
| CN1105560C (zh) | 2003-04-16 |
| AU4120697A (en) | 1998-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69310065D1 (de) | Verwendung von 2-(3,4-Dimethoxycinnamoyl)aminobenzoesäure zur Herstellung eines Arzeimittels zur Behandlung der Restenose | |
| ATE262895T1 (de) | Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis | |
| DE59109222D1 (de) | Verwendung des Wirkstoffs Flupirtin zur Herstellung eines Arzneimittels zur Bekämpfung von Muskelverspannungen | |
| DE60312736D1 (de) | 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems | |
| ATE386520T1 (de) | Kombination von riluzol und levodopa zur behandlung von morbus parkinson | |
| DE69725879D1 (de) | VERWENDUNG VON p-AMINOPHENOLDERIVATEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN | |
| DE69635305D1 (de) | Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma | |
| DE69301750D1 (de) | Verwendung von 1-Alpha,24(R)-Dihydroxy-22(E)-Dehydrovitamin-D3 zur Herstellung eines Arzneimittels zur Behandlung der Osteoporose | |
| DE69432124D1 (de) | Verwendung eines inositoltriphosphatester, zur herstellung eines medikamentes | |
| ATE239470T1 (de) | Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen | |
| ATE232098T1 (de) | Verwendung von efaroxan zur herstellung eines arzneimittels zur behandlung von huntington krankheit | |
| ATE294584T1 (de) | Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz | |
| ATE214605T1 (de) | Verwendung von eliprodil zur herstellung eines arzneimittels zur behandlung von ischämischen störungen der retina oder des sehnervs | |
| ATE189385T1 (de) | Verwendung von benzonaphtalene-derivaten zur herstellung eines arzneimittels zur behandlung von krankheiten des nervensystems | |
| ATE235237T1 (de) | Sertralin zur behandlung von post-myocard-infarkt-patienten | |
| DE3686097D1 (de) | Verwendung von dopamin-agonisten zur herstellung eines arzneimittels zur behandlung von psychostimulant-sucht. | |
| ATE213634T1 (de) | Verwendung von prostaglandinen zur herstellung eines arzneimittels zur prävention und behandlung des sekundären katarakts | |
| DE59510674D1 (de) | Verwendung von selegilin zur behandlung von epileptischen erkrankungen | |
| DE69421705D1 (de) | Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen | |
| DE69620394D1 (de) | Verwendung von forskolin oder diese enthaltende extrakte zur herstellung eines medikaments für die behandlung von alkoholsucht | |
| ATE320263T1 (de) | Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie | |
| DE69632117D1 (de) | Verwendung von 8,9-Dehydroestron zur Herstellung eines Arzneimittels zur Behandlung von durch freie Radikale verursachte Krankheiten | |
| ATE200865T1 (de) | Verwendung von phosphorderivaten von alkaloiden zur behandlung von endokrinopathien | |
| ATE265444T1 (de) | D-ring modifizierte gibberellinverbindungen und ihre herstellung und verwendung | |
| DE69830811D1 (de) | Verwendung von Oxazolidinonderivaten zur Behandlung von Psoriasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |